Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastasis from pancreatic adenocarcinoma

Du, Yan; Bai, Xiu-Mei; Yang, Wei; Zhang, Zhong-Yi; Wang, Song; Wu, Wei; Yan, Kun; Chen, Minhua

doi:10.1080/02656736.2022.2048907

Cited by 5 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

“…Two studies reported on ablation for liver metastases arising from pancreatic cancer are summarized in Table 5 , which were relatively new and published in the year 2021 and 2022 [ 37 , 38 ]. The 1-, 2-, and 3-year OS rates following ablation were reportedly 40–81%, 18–68%, and 53%, respectively, with most patients treated by RFA [ 37 , 38 ]. Yan et al treated 104 patients using a combination of ablation and chemotherapy ( n = 70) or chemotherapy alone ( n = 30); the 1-, 2-, and 3-year OS rates were 81% and 60%, 68% and 20%, and 53% and 0% in the ablation-chemotherapy and chemotherapy alone groups, respectively [ 38 ].…”

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

“…of patients No. of tumors Size of tumors [mm] Follow-up [months] Local tumor control [%] Overall survival [months] Overall survival [%] (Progression-free survival [%]) 1-year 2-year 3-year 4-year 5-year Du et al [ 37 ] 2022 RFA 20 29 26 (mean) – 85 14.6 (mean) 39.5 (26.0) 18.1 (17.3) – – – Yan et al [ 38 ] 2021 RFA/MWA 74 – – 27.8 (median) – 10.8 (median) 81.1 67.6 52.6 – – RFA radiofrequency ablation, MWA microwave ablation …”

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

“…Yan et al reported a tumor number ≤ 2, complete ablation, and multiple ablation as independent prognostic factors [38]. Du et al reported that the abnormal serum CA19-9 level and extrahepatic metastases before RFA were independent prognostic factors for OS [37]. metastasis from ocular and cutaneous melanoma [39].…”

Section: Pancreatic Ductal Adenocarcinomamentioning

confidence: 99%

See 3 more Smart Citations

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

et al. 2022

View full text Add to dashboard Cite

Purpose This review aimed to summarize the treatment outcomes of percutaneous radiofrequency ablation (RFA) and microwave ablation (MWA) for metastatic liver tumors based on the findings of published studies over the last decade. Materials and methods Literature describing the survival outcomes of ablation therapy for liver metastases was explored using the PubMed database on April 26, 2022, and articles published in 2012 or later were selected. The included studies met the following criteria: (i) English literature, (ii) original clinical studies, and (iii) literature describing overall survival (OS) of thermal ablation for metastatic liver tumors. All case reports and cohort studies with fewer than 20 patients and those that evaluated ablation for palliative purposes were excluded. Results RFA was the most commonly used method for ablation, while MWA was used in several recent studies. RFA and MWA for liver metastases from various primary tumors have been reported; however, majority of the studies focused on colorectal cancer. The local control rate by RFA and MWA varied widely among the studies, ranging approximately 50–90%. Five-year survival rates of 20–60% have been reported following ablation for colorectal liver metastases by a number of studies, and several reports of 10-year survival rates were also noted. Conclusion Comparative studies of local therapies for colorectal liver metastases demonstrated that RFA provides comparable survival outcomes to surgical metastasectomy and stereotactic body radiation therapy.

show abstract

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

Section: Results In Each Type Of Primary Tumormentioning

confidence: 99%

Section: Pancreatic Ductal Adenocarcinomamentioning

confidence: 99%

See 2 more Smart Citations

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

et al. 2022

View full text Add to dashboard Cite

show abstract

“…How to prolong the survival time of PCLM patients has been a long‐standing clinical problem, while the prognostic factors of PCLM patients have not been fully understood. Ablation therapy has become a method for the treatment of PCLM, and many studies have proved that it has definite clinical efficacy 13–15 . Therefore, it is urgently needed to assess the prognosis of PCLM patients who underwent ablation.…”

Section: Introductionmentioning

confidence: 99%

A novel nomogram and risk classification system based on inflammatory and immune indicators for predicting prognosis of pancreatic cancer patients with liver metastases

Peng,

Chen

2023

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe study determined to construct a novel predictive nomogram to access the prognosis of pancreatic cancer patients with liver metastases (PCLM).MethodsMedical records included clinical and laboratory variables were collected. The patients were randomly divided into training and validation cohort. First, in the training cohort, the optimal cutoff value of SII, PNI, NLR, PLR were obtained. Then the survival analysis evaluated the effects of above indices on OS. Next, univariate and multivariate analyses were used to identify the independent factors of OS. Moreover, a nomogram was constructed based on LASSO cox analysis. Additionally, the predictive efficacy of the nomogram was evaluated by ROC curve and calibration curve in the training and validation cohort. Finally, a risk stratification system based on the nomogram was performed.ResultsA total of 472 PCLM patients were enrolled in the study. The optimal cutoff values of SII, PNI, PLR and NLR were 372, 43.6, 285.7143 and 1.48, respectively. By combing SII and PNI, named coSII‐PNI, we divided the patients into three groups. The Kaplan–Meier curves demonstrated above indices were correlated with OS. Univariate and multivariate analyses found the independent prognostic factors of OS. Through LASSO cox analysis, coSII‐PNI, PNI, NLR, CA199, CEA, chemotherapy and gender were used to construct the nomogram. Lastly, the ROC curve and calibration curve demonstrated that the nomogram can predict prognosis of PCLM patients. Significant differences were observed between high and low groups.ConclusionsThe nomogram based on immune, inflammation, nutritional status and other clinical factors can accurately predict OS of PCLM patients.

show abstract

The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy

Lu,

Wu,

Miao

et al. 2024

Cancer Immunol Immunother

View full text Add to dashboard Cite

Objective To construct a prognostic model based on MR features and clinical data to evaluate the progression free survival (PFS), overall survival (OS) and objective response rate (ORR) of pancreatic cancer patients with hepatic metastases who received chemoimmunotherapy. Methods 105 pancreatic cancer patients with hepatic metastases who received chemoimmunotherapy were assigned to the training set (n = 52), validation set (n = 22), and testing set (n = 31). Multi-lesion volume of interest were delineated, multi-sequence radiomics features were extracted, and the radiomics models for predicting PFS, OS and ORR were constructed, respectively. Clinical variables were extracted, and the clinical models for predicting PFS, OS and ORR were constructed, respectively. The nomogram was jointly constructed by radiomics model and clinical model. Result The ORR exhibits no significant correlation with either PFS or OS. The area under the curve (AUC) of nomogram for predicting 6-month PFS reached 0.847 (0.737–0.957), 0.786 (0.566–1.000) and 0.864 (0.735–0.994) in the training set, validation set and testing set, respectively. The AUC of nomogram for predicting 1-year OS reached 0.770 (0.635–0.906), 0.743 (0.479–1.000) and 0.818 (0.630–1.000), respectively. The AUC of nomogram for predicting ORR reached 0.914 (0.828–1.00), 0.938 (0.840–1.00) and 0.846 (0.689–1.00), respectively. Conclusion The prognostic models based on MR imaging features and clinical data are effective in predicting the PFS, OS and ORR of chemoimmunotherapy in pancreatic cancer patients with hepatic metastasis, and can be used to evaluate the prognosis of patients.

show abstract

Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastasis from pancreatic adenocarcinoma

Cited by 5 publications

References 37 publications

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade

A novel nomogram and risk classification system based on inflammatory and immune indicators for predicting prognosis of pancreatic cancer patients with liver metastases

The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy

Contact Info

Product

Resources

About